Research
Hormonal
For Semaglutide, higher doses are associated with a higher risk of intolerable gastrointestinal adverse reactions.
If you are taking Semaglutide and experiencing intolerable gastrointestinal side effects, discuss with your doctor whether a lower dose (e.g., 0.5mg) might be sufficient to manage your condition with fewer side effects, as higher doses (1mg) are associated with a higher risk of these reactions.
ModerateSupportsMEDIUM confidence
STEP 4 results showed that Semaglutide 0.5 mg q.w caused a lower risk of intolerable GI AEs than Semaglutide (OR=0.66, 95%CI 0.47,0.91)... Semaglutide 1mg q.w (99.6) was associated with a higher risk than 0.5mg q.w (74.8).
Why this rating
Based on a subset of 4 articles in STEP 4, which is a smaller analysis than STEP 1-2.
Source
GLP-1RAs caused gastrointestinal adverse reactions of drug withdrawal: a system review and network meta-analysis
Ziqi Zhang et al. · Frontiers in Endocrinology · 2023
DOI 10.3389/fendo.2023.1149328
Meta-analysis · 64 studiesCited 38×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) cause a significantly higher rate of intolerable gastrointestinal adverse reactions leading to drug withdrawal compared to other hypoglycemic agents (Insulin, SGLT2i, DPP4i, TZD) and placebo.Good
- Among GLP-1RAs, Dulaglutide has the lowest risk of causing intolerable gastrointestinal adverse reactions, while Semaglutide and Liraglutide have the highest risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →